Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis

<div>Network plot for all interventions for objective response rate (a) and 6 months progression-free survival (b) in the PIK3CA-mutated subgroup and the PIK3CA-mutated and wild-type total subgroup patients with breast cancer.</div>

BioMed Research International

fig3

Figure 3

Figure 3: Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis 

Figure 3 | Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis 